Despite longer waiting list times, graft and recipient survival maintained and waiting list mortality unchanged
FRIDAY, Oct. 14, 2022 (HealthDay News) — The COVID-19 pandemic was associated with increased waiting list times among pediatric patients awaiting a heart transplant (HT) in the United States, according to a research letter published online Oct. 7 in JAMA Network Open.
John Iguidbashian, M.D., from the University of Colorado School of Medicine in Aurora, and colleagues used data from the United Network for Organ Sharing to evaluate if the COVID-19 pandemic was associated with increased waiting list times among pediatric U.S. HT recipients. Wait times were compared for November 1, 2018, to February 28, 2020 (prepandemic group; 626 patients), and from March 1, 2020, to June 30, 2021 (pandemic group; 610 patients).
The researchers found that pandemic HT recipients had significantly increased mean waiting list times (157.4 days) versus nonpandemic HT controls (126 days; mean difference, 32 days). Waiting list survival remained similar between the groups. Despite longer wait times, post-HT recipient and graft survival were maintained among pandemic and nonpandemic HT recipients. There were significant mean decreases observed in postoperative length of stay among pandemic HT recipients (31 days) versus nonpandemic HT recipients (40 days; mean difference, −9 days).
“Survival and quality of life among children awaiting HT will depend on a collaborative commitment to standardized decision making and critical outcomes analyses,” the authors write.
Biomarkers Plus Kidney Donor Profile Index Improve Prediction of Concordant Allograft Outcomes
Short-Term Pretransplant Dialysis Does Not Affect Kidney Transplant Outcomes
Patient Education Increases Skin Cancer Screening in Stem Cell Transplant Survivors
Lung Transplant Can Prolong Survival in Stage IV NSCLC
Adenotonsillectomy Tied to Increase in Respiratory Tract Infections in Children
Thymic Radiation Linked to Worse Outcomes in Patients With NSCLC
All-Cause Mortality Elevated for Adult Five-Year Survivors of Hodgkin Lymphoma
Robotic Arm-Assisted TKR Offers Similar Outcome to Conventional TKR